Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC).
However, the development of drug resistance is common, and the mechanisms of lenvatinib …

The survival benefit derived from sorafenib treatment for patients with hepatocellular
carcinoma (HCC) is modest due to acquired resistance. Targeting cancer stem cells (CSC) …

Abstract Background: Multikinase inhibitors (MKIs) have been shown to improve survival in
patients with hepatocellular carcinoma (HCC) compared with placebo. Distinct from other …

Srchomology-2-domain-containing PTP 2 (SHP2) is a nonreceptor phosphatase encoded by
the PTPN11 gene. Over expression of SHP2 is associated with various human diseases …

Senescence is a special state of tumor suppression induced by cell cycle arrest. However,
releasing senescence-associated secretory phenotypes by senescent cells could provide …

Background Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all
solid tumors with a 5‐year survival rate of less than 10% and a median survival of 6 months …

The drug discovery panorama is cluttered with promising therapeutic targets that have been
deserted because of inadequate authentication and screening failures. Molecular targets …

Background The survival benefit of sorafenib, the most used drug for advanced
hepatocellular carcinoma (HCC), is unsatisfactory due to the development of adaptive …

Introduction: Drug-drug interactions (DDIs) are the main causes of the adverse drug
reactions and the nature of the functional and molecular complexity of drugs behavior in the …

Three-dimensional organoids, which resemble the pathophysiology and structural
architecture of the original tissues, are a preferable in vitro model system for assessing …